[go: up one dir, main page]

PE20020337A1 - IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2 - Google Patents

IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2

Info

Publication number
PE20020337A1
PE20020337A1 PE2001000752A PE2001000752A PE20020337A1 PE 20020337 A1 PE20020337 A1 PE 20020337A1 PE 2001000752 A PE2001000752 A PE 2001000752A PE 2001000752 A PE2001000752 A PE 2001000752A PE 20020337 A1 PE20020337 A1 PE 20020337A1
Authority
PE
Peru
Prior art keywords
alkyl
cycline
cdk5
cdk2
kinase inhibitors
Prior art date
Application number
PE2001000752A
Other languages
Spanish (es)
Inventor
Michael Kirk Ahlijanian
Christopher Blair Cooper
Christopher John Helal
Anabella Villalobos
Frank Samuel Menniti
Mark Allen Sanner
Patricia Ann Seymour
Lit-Fui Lau
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20020337A1 publication Critical patent/PE20020337A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I EN LA QUE R1 ES UN ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, O SUSTITUIDOS CON R5, ENTRE OTROS; R2 ES H, F, CH3, CH, COOR7; R3 ES CONR9, COO, -C(=O)(CR10R11)n, ENTRE OTROS; R4 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ENTRE OTROS; R5 ES F, Cl, Br, I, NITRO, ENTRE OTROS; R7, R8, R9 SON H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8, CICLOALQUILO C3-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS N-(1-CICLOBUTIL-1H-IMIDAZOL-4-IL)-2-QUINOLIN-6-IL-ACETAMIDA, N-(1-CICLOPENTIL-1H-IMIDAZOL-4-IL)-2-(4-METOXI-FENIL)-ACETAMIDA, N-[1-(CIS-3-FENIL-CICLOBUTIL)-1H-IMIDAZOL-4-IL]-2-QUINOLIN-6-IL-ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS DERIVADOS DE IMIDAZOL SON INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINA cdk5 Y cdk2 Y SON UTILES PARA EL TRATAMIENTO DEL CANCER, ENFERMEDADES NEURODEGENERATIVASREFERS TO COMPOUNDS OF FORMULA I IN WHICH R1 IS AN ALKYL C1-C8, ALKYL C2-C8, ALKINYL C2-C8, CYCLOALKYL C3-C8, CYCLOALKENYL C4-C8, OR SUBSTITUTED WITH R5, AMONG OTHERS; R2 IS H, F, CH3, CH, COOR7; R3 IS CONR9, COO, -C (= O) (CR10R11) n, AMONG OTHERS; R4 IS C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKINYL, C3-C8 CYCLOALKYL, C4-C8 CYCLOALKENYL, AMONG OTHERS; R5 IS F, Cl, Br, I, NITRO, AMONG OTHERS; R7, R8, R9 ARE H, C1-C8 ALKYL, C2-C8 ALKENYL, C2-C8 ALKYL, C3-C8 CYCLOALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE N- (1-CYCLOBUTYL-1H-IMIDAZOL-4-IL) -2-QUINOLIN-6-IL-ACETAMIDE, N- (1-CYCLOPENTIL-1H-IMIDAZOL-4-IL) -2- (4- METHOXY-PHENYL) -ACETAMIDE, N- [1- (CIS-3-PHENYL-CYCLOBUTIL) -1H-IMIDAZOL-4-IL] -2-QUINOLIN-6-IL-ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. IMIDAZOLE DERIVATIVES ARE KINASE INHIBITORS DEPENDENT ON CDK5 AND CDK2 CYCLINE AND ARE USEFUL FOR THE TREATMENT OF CANCER, NEURODEGENERATIVE DISEASES

PE2001000752A 2000-07-31 2001-07-25 IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2 PE20020337A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22172400P 2000-07-31 2000-07-31

Publications (1)

Publication Number Publication Date
PE20020337A1 true PE20020337A1 (en) 2002-05-08

Family

ID=22829075

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000752A PE20020337A1 (en) 2000-07-31 2001-07-25 IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2

Country Status (35)

Country Link
EP (1) EP1305295A1 (en)
JP (2) JP4166084B2 (en)
KR (1) KR20030019644A (en)
CN (1) CN1444567A (en)
AP (1) AP2001002232A0 (en)
AR (1) AR032629A1 (en)
AU (1) AU2001270944A1 (en)
BG (1) BG107469A (en)
BR (1) BR0112862A (en)
CA (1) CA2418115A1 (en)
CR (1) CR6861A (en)
CZ (1) CZ2003225A3 (en)
DO (1) DOP2001000220A (en)
EA (1) EA200300097A1 (en)
EC (1) ECSP034445A (en)
EE (1) EE200300049A (en)
GT (1) GT200100147A (en)
HR (1) HRP20030048A2 (en)
HU (1) HUP0303069A3 (en)
IL (1) IL153787A0 (en)
IS (1) IS6662A (en)
MA (1) MA26932A1 (en)
MX (1) MXPA03000939A (en)
NO (1) NO20030472L (en)
NZ (1) NZ523272A (en)
OA (1) OA12345A (en)
PA (1) PA8523701A1 (en)
PE (1) PE20020337A1 (en)
PL (1) PL365134A1 (en)
SK (1) SK1042003A3 (en)
SV (1) SV2002000571A (en)
TN (1) TNSN01114A1 (en)
UY (1) UY26862A1 (en)
WO (1) WO2002010141A1 (en)
ZA (1) ZA200300819B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384160T3 (en) 1999-01-13 2012-07-02 Bayer Healthcare Llc Diphenyl ureas substituted with omega-carboxy aryl as kinase inhibitors p38
RU2319693C9 (en) 1999-01-13 2008-08-20 Байер Копэрейшн Derivatives of urea (variants), pharmaceutical composition (variants) and method for treatment of diseases associated with cancer cells growth (variants)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
EP1527070B1 (en) 2002-06-14 2013-01-09 Merck Serono SA Azole methylidene cyanide derivatives and their use as protein kinase modulators
DE10233817A1 (en) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
ES2288694T3 (en) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation DIARIL UREAS FOR DISEASES MEDIATED BY THE RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES.
UA84156C2 (en) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DE602005007717D1 (en) * 2004-03-23 2008-08-07 Pfizer Prod Inc IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2295426A1 (en) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
ES2337164T3 (en) 2004-09-21 2010-04-21 Astellas Pharma Inc. DERIVATIVES OF AMINOALCOHOL.
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009508934A (en) 2005-09-22 2009-03-05 ファイザー・プロダクツ・インク Imidazole compounds for the treatment of neurological disorders
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
RU2009119181A (en) 2006-10-21 2010-11-27 Эбботт Гмбх Унд Ко.Кг (De) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS Glycogen synthase-kinase-3 inhibitors
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
ES2418457T3 (en) * 2008-04-24 2013-08-13 Abbott Gmbh & Co. Kg Derivatives of 1- (7- (hexahydropyrrolo [3,4-c] pyrrol-2 (1H) -yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea and related compounds such as glycogen synthase inhibitors kinase 3 (GSK-3)
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5998142B2 (en) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CA2893597C (en) 2012-12-07 2021-06-29 Chemocentryx, Inc. Diazole lactams
DK2935227T3 (en) 2012-12-21 2017-12-04 Chemocentryx Inc DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
WO2015119249A1 (en) * 2014-02-07 2015-08-13 国立大学法人東京医科歯科大学 Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
WO2017040611A1 (en) 2015-08-31 2017-03-09 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
PL3439653T3 (en) 2016-04-07 2021-07-05 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
CN107698567B (en) * 2017-10-25 2020-09-15 西南大学 Isatin azole alcohol compound and preparation method and medical application thereof
WO2020010155A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
KR20250030524A (en) 2019-08-09 2025-03-05 화이자 인코포레이티드 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
AU2021359129A1 (en) * 2020-10-16 2023-06-01 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN112250636A (en) * 2020-11-09 2021-01-22 广西科技大学 5-aminoimidazole compound and synthesis method thereof
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
EP4396159A1 (en) 2021-09-01 2024-07-10 Springworks Therapeutics, Inc. Synthesis of nirogacestat
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
CN116983313A (en) * 2023-07-13 2023-11-03 四川大学 New application of NU6300

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
WO1999065897A1 (en) * 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (en) * 1999-02-19 2002-05-30 Lilly Co Eli SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED
DE69912808T2 (en) * 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Use of hymenialdisine and its derivatives for the preparation of therapeutic agents

Also Published As

Publication number Publication date
OA12345A (en) 2004-04-13
HUP0303069A2 (en) 2004-03-01
IS6662A (en) 2002-12-19
TNSN01114A1 (en) 2005-11-10
BR0112862A (en) 2003-07-01
AP2001002232A0 (en) 2001-09-30
ECSP034445A (en) 2003-03-10
JP2008255123A (en) 2008-10-23
CA2418115A1 (en) 2002-02-07
GT200100147A (en) 2002-06-25
UY26862A1 (en) 2002-02-28
PL365134A1 (en) 2004-12-27
CN1444567A (en) 2003-09-24
HUP0303069A3 (en) 2004-04-28
MXPA03000939A (en) 2003-06-24
CR6861A (en) 2004-03-11
AU2001270944A1 (en) 2002-02-13
PA8523701A1 (en) 2002-04-25
NO20030472L (en) 2003-03-27
EA200300097A1 (en) 2003-06-26
DOP2001000220A (en) 2002-05-15
AR032629A1 (en) 2003-11-19
ZA200300819B (en) 2004-04-20
SK1042003A3 (en) 2004-05-04
IL153787A0 (en) 2003-07-31
SV2002000571A (en) 2002-10-24
CZ2003225A3 (en) 2004-02-18
MA26932A1 (en) 2004-12-20
JP2004505111A (en) 2004-02-19
NO20030472D0 (en) 2003-01-30
KR20030019644A (en) 2003-03-06
JP4166084B2 (en) 2008-10-15
HRP20030048A2 (en) 2003-04-30
BG107469A (en) 2003-09-30
EE200300049A (en) 2004-10-15
WO2002010141A1 (en) 2002-02-07
EP1305295A1 (en) 2003-05-02
NZ523272A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
PE20020337A1 (en) IMIDAZOLE DERIVATIVES AS CYCLINE-DEPENDENT KINASE INHIBITORS cdk5 AND cdk2
PE20191755A1 (en) PYRAZOLE DERIVATIVES AS MALT 1 INHIBITORS
UY29633A1 (en) OXINDOL DERIVATIVES
PE20220016A1 (en) INHIBITORS AND METHODS OF USE OF KCNT1
ECSP105253A (en) DERIVATIVES OF 5-PHENYLTIAZOL AND USE AS INHIBITORS OF PI3 CINASA
HN2004000232A (en) "PIRROLO DERIVATIVES (3,4-C) PIRAZOL ACTIVE AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM."
UY28514A1 (en) NEW COMPOUNDS
AR041184A1 (en) DERIVATIVES OF BENZOPIRANONAS, INHIBITORS OF CYCLINE DEPENDENT KINES AND THEIR USE
CU23550B7 (en) PIRROLO-PIRAZOL DERIVATIVES REPLACED AS QUINASA INHIBITORS
AR049578A1 (en) HYDANTOIN DERIVATIVES, OBTAINING PROCESSES AND PHARMACEUTICAL COMPOSITIONS
MXPA05012573A (en) Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors.
ECSP055582A (en) BENZOTIAZOL DERIVATIVES THAT HAVE BETA-2-ADRENORRECEPTOR AGONIST ACTIVITY
AR047076A1 (en) PIRROLOTRIAZINE COMPOUNDS AS THYROSINE KINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS
PE20020470A1 (en) PIRAZOLE DERIVATIVES AS INHIBITORS OF ENZYMES PROTEIN KINASES
PE20020504A1 (en) APOPTOSIS-PROMOTING N-ACILSULFONAMIDES
PE20050462A1 (en) COMPOUNDS OF 5,7-DIAMINOPYRAZOLE [4,3-d] PYRIMIDINES AS INHIBITORS OF PHOSPHODIESTERASE TYPE 5 (PDE-5)
AR057109A1 (en) BENZIMIDAZOLS REPLACED AND METHODS TO USE THEM AS INHIBITORS OF KINASES ASSOCIATED WITH TUMORIGENESIS
AR066583A1 (en) DERIVATIVES OF 3,3-ESPIROINDOLINONA
UY30316A1 (en) SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS
BR112019021853A2 (en) VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS OF THE SAME
ECSP099767A (en) DERIVATIVES OF N '- (PHENYL) -N- (MORFOLIN-4-IL-PIRIDIN-2-IL) -PIRIMIDINA-2, 4-DIAMINE AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE AFFECTIONS
PE20200848A1 (en) Phenylpyridine derivatives with dual anti-BTK and anti-ITK activity and pharmaceutical compositions containing them
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
AR040274A1 (en) DERIVATIVES OF 1 - [(INDOL-3-IL) CARBONIL] PIPERAZINE AS CANABINOID AGONISTS IN THE TREATMENT OF PAIN AND PHARMACEUTICAL COMPOSITIONS
CO2024015820A2 (en) Heteroaryl compounds for pain treatment

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed